Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast Enhanced 3D Echocardiography for Right Ventricular Volumes in Repaired Congenital Heart Disease
NCT05186415Phase 2Completed
- Sponsor
- Nemours Children's Health
- Start
- Aug 2022
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulfur hexafluoride lipid type a microspheres in congenital heart disease (CHD), pulmonary insufficiency (PR) and tetralogy of Fallot (TOF), sponsored by Nemours Children's Health. Primary endpoints: Accuracy of 3D Echocardiography Based Measurements of Right Ventricular Size Compared to MRI Derived Values at Day 0, Accuracy of 3D Echocardiography Based Measurements of Right Ventricular Function Compared to MRI Derived Values at Day 0 and 1 more. Started Aug 2022; status: completed.
02
Drugs
sulfur hexafluoride lipid type a microspheres
03
Conditions
congenital heart disease (CHD)pulmonary insufficiency (PR)tetralogy of Fallot (TOF)
Beyond the preview
Go deeper on NCT05186415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186415.